Business Wire
19 Oct 2025, 14:30 UTC · 48w ago
Verdict
Headline takes no side. We score SMMT +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company announced Phase III trial results for its potential first-in-class investigational antibody.
More positive than 87% of ticker scores this week
As the trial sponsor, Akeso benefits from the presentation of Phase III data for ivonescimab.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 77% of relationship scores this week
[mutual] Summit Therapeutics identifies Akeso, Inc. as its partner for the Phase III HARMONi-6 trial of ivonescimab.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
1d ago
−22.8%
Price is moving against the score
$16.20 vs $20.99 close before publication (Oct 17) · not market-adjusted
SMMT chart →
